- In March 2024, Astellas Pharma US, Inc. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug and pediatric exclusivity to CRESEMBA (isavuconazonium sulfate) for the treatment of invasive aspergillosis and invasive mucormycosis in pediatric patients. This designation offers market exclusivity and bolsters the company’s reputation for addressing significant unmet medical needs. Furthermore, it is expected to drive revenue growth through expanded usage of CRESEMBA in pediatric populations
- In October 2023, Basilea Pharmaceutica Ltd completed the acquisition of Gravitas Therapeutics Inc., which includes a clinical-stage antifungal compound that utilizes a novel mechanism of action to target invasive mold infections caused by Aspergillus species. This acquisition strengthens Basilea's pipeline by introducing a distinctive antifungal therapy, enhancing its competitive advantage in the market. Additionally, it addresses a critical unmet medical need, aligns with the company’s strategic growth objectives, and opens up further opportunities for development and commercialization
Frequently Asked Questions
The market is segmented based on Segmentation, By Treatment (Bronchodilator, Antibiotics, Embolization, Vaccinations, Corticosteroids, Physiotherapy, and others), Diagnosis (Blood Tests, X-ray, Bronchoscopy, Pulmonary Function Tests, and Others), Dosage (Tablet, Injection, and Others), Route of Administration (Oral, Intravenous, and Others), End Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2032
.
The Global Allergic Bronchopulmonary Aspergillosis Treatment Market size was valued at USD 1.14 USD Billion in 2024.
The Global Allergic Bronchopulmonary Aspergillosis Treatment Market is projected to grow at a CAGR of 14.23% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
